NewCelX (NLSP) details post-merger business and strategy update

Rhea-AI Filing Summary

NewCelX Ltd. filed a Form 6-K to furnish a press release and investor presentation issued on November 3, 2025. The materials provide a business and strategic roadmap update following the closing of NewCelX’s merger with NLS Pharmaceutics Ltd.

The filing itself mainly serves to formally provide these two documents to investors and regulators as Exhibits 99.1 and 99.2.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of November 2025

Commission File Number: 001-39957

NEWCELX LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

CONTENTS

Press Release

On November 3, 2025, NewcelX Ltd., a corporation incorporated under the laws of Switzerland (“NewCelX” or the “Company”), issued a press release titled: “NewCelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.” A copy of this press release is furnished herewith as Exhibit 99.1.

Investor Presentation

On November 3, 2025, the Company made available an investor presentation on its website. A copy of the investor presentation is furnished herewith as Exhibit 99.1.

EXHIBIT INDEX

Exhibit Number		Description of Document
99.1		Press release titled: “NewCelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.”
99.2		Investor Presentation

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NewcelX Ltd.
Date: November 3, 2025	By:	/s/ Ronen Twito
		Name:	Ronen Twito
		Title:	Chief Executive Officer

2

FAQ

What did NewCelX (NLSP) report in its November 2025 Form 6-K?

NewCelX Ltd. furnished a press release and an investor presentation that provide a business and strategic roadmap update following the closing of its merger with NLS Pharmaceutics Ltd.

What event prompted NewCelX (NLSP) to issue this Form 6-K?

The Form 6-K is tied to NewCelX’s closing of its merger with NLS Pharmaceutics Ltd. and the company’s related update on its business and strategic roadmap.

Which exhibits are included with NewCelX Ltd.’s Form 6-K?

The filing lists two exhibits: Exhibit 99.1, a press release titled “NewCelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.,” and Exhibit 99.2, an investor presentation.

Does the NewCelX (NLSP) Form 6-K contain detailed financial results?

No detailed financial results are described in the text; the Form 6-K focuses on furnishing a press release and an investor presentation about the company’s post-merger roadmap.

Where is NewCelX Ltd.’s principal executive office located?

NewCelX Ltd.’s principal executive office is located at The Circle 6, 8058 Zurich, Switzerland.

Who signed the NewCelX (NLSP) Form 6-K?

The Form 6-K was signed on behalf of NewCelX Ltd. by Ronen Twito, the company’s Chief Executive Officer.